Patent ID: 11896604
Assignee: GLYCOM A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 9:
10. A method comprising:
selecting a non-infant human experiencing lactose intolerance and one or more gastrointestinal symptoms of lactose intolerance, the gastrointestinal symptoms selected from diarrhea, abdominal pain, cramping, bloating, and flatulence;
selecting a daily dose comprising an effective amount of one or more neutral human milk oligosaccharides (HMOs) selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, the amount effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human; and
increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and reducing at least one of the one or more gastrointestinal symptoms of the lactose intolerance by administering to the non-infant human the daily dose of from about 3 g to about 10 g of the one or more HMOs during an initial treatment period.